SCN1A and epilepsy: In 73/293 (25%) patients, there was a treatment change prompted by the genetic diagnosis (16 of them also had PM trialled), but not directly related to known pathophysiological mechanisms (eg, valproate and stiripentol in SCN1A-related epilepsies).